Full-Time
CMC Shipping Associate
Posted on 6/21/2024
Arrowhead Pharmaceuticals
501-1,000 employees
Develops RNAi-based therapies for diseases
Compensation Overview
$60k - $75kAnnually
Junior, Mid
Fitchburg, WI, USA
- Bachelor’s degree in supply chain, logistics, science or related discipline with two years of life science experience in shipping and logistics (or high school diploma with eight years of experience including three years in a GMP environment)
- Current/ previous certifications required for shipping (i.e., DOT, IATA)
- Experience executing transactions in ERP systems
- Excellent attention to detail and problem solving skills
- Excellent interpersonal skills
- Excellent written and verbal communication skills
- Proficient knowledge of GMP procedure and policy
- Proficient with Microsoft Office Suite
- Serve as a point of contact for shipments of raw materials, drug substance, and international shipping requests
- Execute and track domestic and international shipments including preparation of customs clearance paperwork
- Coordinate transport raw materials or drug substance to third party facilities, communicating with drivers and air partners to ensure efficient delivery of packages
- Troubleshoot shipment issues, delays, and change in requirements
- Maintain a clean and organized shipping area with adequate supply of shipping materials
- Work closely with couriers when package exemptions arise
- Collaborate with vendors on empty returnable drums/totes (10L to 1250L) for shipments
- Support writing and investigations of non-conformances pertaining to shipping and transportation processes
- Perform all responsibilities in compliance with internal SOPs and external regulations. Brings compliance issues to the attention of management
- Performs other duties as assigned, in a dynamic environment
Arrowhead Pharmaceuticals develops medicines aimed at treating severe diseases by targeting and silencing specific genes. The company uses RNA interference (RNAi), a natural process that reduces gene expression, to create therapies that can potentially stop or reverse diseases like cystic fibrosis and hepatitis B. Their approach involves a variety of RNA chemistries and effective delivery methods to ensure that the target genes are significantly reduced in activity. Unlike many competitors, Arrowhead focuses specifically on RNAi-based therapies, which allows them to address medical needs that are not met by existing treatments. The goal of Arrowhead Pharmaceuticals is to provide new treatment options for patients suffering from genetic disorders, leveraging their expertise and partnerships to bring these therapies to market.
Company Stage
IPO
Total Funding
$899.9M
Headquarters
Pasadena, California
Founded
2004
Simplify's Take
What believers are saying
- Arrowhead's recent $450 million funding round provides substantial financial resources to advance its drug pipeline and expand research initiatives.
- Positive Phase 2 data for plozasiran and the initiation of an Expanded Access Program highlight the company's commitment to addressing unmet medical needs.
- The company's diversified pipeline, including treatments for cystic fibrosis, hepatitis B, and myotonic dystrophy, offers multiple avenues for success.
What critics are saying
- The high costs and lengthy timelines associated with drug development could strain Arrowhead's financial resources despite recent funding.
- Regulatory hurdles and the potential for clinical trial failures pose significant risks to the company's drug approval process.
What makes Arrowhead Pharmaceuticals unique
- Arrowhead Pharmaceuticals leverages RNA interference (RNAi) technology to target and silence disease-causing genes, setting it apart from traditional pharmaceutical approaches.
- The company's proprietary TRiM platform enables tissue-specific targeting, enhancing the efficacy and safety of its therapies.
- Strategic partnerships with major pharmaceutical companies like Takeda bolster Arrowhead's credibility and expand its research capabilities.